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ABSTRACT 
Major depression (MD) is a common psychiatric disorder that represents a 
leading cause of disability in the world. It is known that this complex disease 
originates from the interaction between many factors of different nature -a 
genetic background of susceptibility, biological, social and environmental stimuli- 
that act in concert leading to the development of the illness. Despite the 
increased knowledge of MD neurobiology, an effective improvement in the overall 
impact of pharmacotherapy is still lacking, possibly because a number of systems 
that are affected in mood disorders may not be adequately modulated by 
pharmacological treatments. Currently there is strong evidence that depression 
involves alterations of the immune/inflammatory system. In particular MD shows 
an elevated comorbidity with cancer, rheumatoid arthritis, cardiovascular and 
neurodegenerative diseases, all characterized by inflammatory alterations. 
Moreover, the treatment of Hepatitis C virus with IFN predisposes to the 
development of clinically significant depression. On these bases, the purpose of 
our study was to analyze the cerebral expression of several mediators of the 
immune/inflammatory system in an animal model of depression based on the 
environmental component of the disease -the rat exposed to chronic mild stress 
(CMS)-, to elucidate the role of inflammation on the generation of the anhedonic 
phenotype and to evaluate the ability of pharmacological intervention in 
modulating the behavioral-associated inflammatory alterations. To this aim, rats 
exposed to CMS for two weeks were tested with the sucrose consumption test to 
assess the insurgence of an anhedonic phenotype, then molecular analyses were 
carried out on dorsal, ventral hippocampus and on prefrontal cortex, three brain 
regions mainly involved in the etiology of depression. Afterward a group of 
anhedonic animals underwent to five further weeks of CMS with a parallel 
treatment with the tricyclic antidepressant imipramine and the atipical 
antipsychotic lurasidone. At the end of the treatment, molecular analyses on 
inflammatory mediators were conducted. Our findings indicate that the stress-
induced anhedonic phenotype is associated to an altered expression of specific 
mediators of immune/inflammatory system and that pharmacological treatment is 
not only able to normalize the anhedonic phenotype, but also inflammatory 
changes. These data suggest that the immune/inflammatory alterations are not a 
merely consequence of stress exposure, but they may contribute to the subject’s 
vulnerability to depression and support the idea that this system may serve as a 
viable therapeutic target for more effective antidepressant drugs. 
 
